GlassScriptPhysician profile
Henry H Rhee
NPI 1265489868
$15,274.84
in general payments reported to CMS, 2019-2025
25 companies · $2,734 in 2025
The $2,734 reported for 2025 was more than what 88% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,639 · 2020: $1,690 · 2021: $1,906 · 2022: $2,620 · 2023: $2,415 · 2024: $2,270 · 2025: $2,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,129 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,128.98 |
| Education | $291.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,760.15 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $2,401.10 | 2019-2025 | Veklury, Biktarvy |
| Abbvie INC. | $1,751.57 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,483.91 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Melinta Therapeutics, LLC | $1,163.20 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Theratechnologies INC. | $894.52 | 2019-2025 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $670.16 | 2019-2025 | Mytesi |
| La Jolla Pharmaceutical Company | $669.92 | 2022-2025 | Xerava, Xacduro, Zevtera |
| Insmed, INC. | $624.59 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $612.97 | 2019-2023 | Symtuza |
| Shionogi INC | $578.85 | 2024-2025 | Fetroja |
| Janssen Products, LP | $355.46 | 2019-2022 | |
| Allergan, INC. | $277.30 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $221.90 | 2020-2024 | Nuzyra |
| Aimmune Therapeutics, INC. | $182.61 | 2023-2025 | Vowst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $159.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $115.92 | 2021-2022 | |
| Astellas Pharma US INC | $95.79 | 2019-2024 | Cresemba |
| Ferring Pharmaceuticals INC. | $83.93 | 2022-2024 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $61.83 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $32.46 | 2025 | |
| Mylan Pharmaceuticals INC. | $23.02 | 2019 | |
| Mylan Institutional INC. | $19.97 | 2019 | |
| Myriad Genetic Laboratories, INC. | $17.93 | 2025 | Myrisk |
| Neurelis, INC. | $15.95 | 2025 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.